Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Korro Bio
Biotech
Korro lays off staff as lead drug disappoints, Novo pauses pact
The biotech, which suffered a 79% stock drop in the wake of the news, is laying off 34% of its employees to extend its cash runway deeper into 2027.
Nick Paul Taylor
Nov 13, 2025 7:20am
Korro lays off 20% to fund genetic med trials, Novo collab
May 8, 2025 10:00am
FDA rocked by leadership shake-ups—Chutes & Ladders
Apr 4, 2025 8:30am
Novo Nordisk signs $530M biobucks deal to sing in Korro's opera
Sep 16, 2024 9:40am
Korro Bio merges with off-pitch Frequency, tacks on $117M
Jul 14, 2023 9:50am
Billy Dunn departs FDA—Chutes & Ladders
Mar 3, 2023 9:30am
